The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.
Sonya Collins
Advertisement
Articles by Sonya Collins
Advertisement
Latest Updated Articles
10 Years in CLL: Top Advances From 2012-2022April 14th 2022
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Advanced Renal Cell Carcinoma: Selecting Between IO/TKI and IO/IO Combination Therapy
2
FDA Approves Subcutaneous Isatuximab for Multiple Myeloma
3
FDA Approves Perioperative Pembrolizumab Plus Enfortumab Vedotin for MIBC
4
First Patient Treated With PSMA-Targeted Actinium-225 Alpha Emitter in mCRPC
5